Sun Young Kim

National Cancer Center

Papers

1

Total Citations

25

H-Index

1

About

Sun Young Kim is a leading figure in gastrointestinal oncology, with a particular focus on optimizing treatment strategies for rectal cancer. Her research centers on the integration of chemoradiotherapy and surgical timing to improve patient outcomes while minimizing toxicity. In her landmark phase II multi-institutional clinical trial (KROG 11-02), she demonstrated that a two-week course of preoperative chemoradiotherapy followed by delayed surgery is both feasible and effective for rectal cancer, offering a shorter, more tolerable regimen without compromising oncologic results. This work, cited over 25 times, has contributed to evolving paradigms in neoadjuvant therapy. Beyond this, Kim’s broader contributions include refining multimodal treatment protocols and exploring biomarkers to personalize therapy. Her studies have been instrumental in shaping clinical guidelines and have earned her recognition as a key collaborator in Korean Radiation Oncology Group trials. For students and researchers, Kim’s work exemplifies how pragmatic, patient-centered trial design can advance evidence-based practice in radiation oncology.

Research Focus

Key Achievements

1
H-Index
1
Papers
25
Total Citations
25
Avg Citations/Paper
🏆 Most Cited Paper
Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: A phase II multi-institutional clinical trial (KROG 11-02)
25 citations · 2014
📈 Most Prolific Year: 2014 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: National Cancer Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago